Loading...
XNSE
ALPA
Market cap18mUSD
Nov 12, Last price  
85.15INR
Name

Alpa Laboratories Ltd

Chart & Performance

D1W1MN
XNSE:ALPA chart
P/E
11.94
P/S
1.69
EPS
7.13
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
1.88%
Revenues
1.06b
-5.91%
1,013,635,0001,292,751,7921,216,848,000934,367,882828,672,869551,298,721561,085,000567,083,000573,939,000535,900,000625,421,000618,978,000764,219,000848,704,000964,135,0001,105,133,000924,102,0001,087,390,0001,124,519,0001,058,096,000
Net income
150m
-23.04%
64,007,00069,243,1623,786,0007,965,0009,039,4105,284,518-43,680,000-51,548,000-13,977,00068,461,00025,200,00027,900,00010,117,00018,534,00072,471,000140,917,000125,828,000167,765,000195,031,000150,098,000
CFO
124m
+34.64%
-68,207,00051,728,00020,687,0008,631,89849,001,20241,828,75725,583,00080,646,000-18,353,000-218,532,000169,900,00018,400,000-10,050,000177,820,000-17,000,00099,403,00089,044,00036,487,00092,373,000124,372,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1967 and based in Indore, India, Alpa Laboratories Limited specializes in the development and marketing of a diverse portfolio of finished pharmaceutical dosage forms. Their extensive product range includes ethical, generic, and over-the-counter (OTC) medications, presented as injections, tablets, capsules, eye/ear drops, ointments, creams, and gels, catering to both human and veterinary needs. The company's therapeutic categories are broad, encompassing anti-infectives (such as antibacterials, antibiotics, antifungals, antiprotozoals, and antivirals), analgesics, anti-inflammatory drugs, cough and cold remedies, cardiovascular medications, anti-diabetics, nutritional supplements, psychotropic treatments, and dermatological, ophthalmic, and otic preparations. Alpa Laboratories distributes its products throughout India through a network of distributors, retail chemists, pharmacies, and hospitals. Additionally, the company maintains an international presence, exporting to regions including South and Central America, Africa, Asia, Russia, Ukraine, and Kazakhstan.
IPO date
Aug 01, 2007
Employees
Domiciled in
IN
Incorporated in
IN

Valuation

Title
INR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT